Mounjaro vs. Rybelsus
See how Mounjaro and Rybelsus compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Mounjaro is a once-weekly injection that acts on two hormone pathways, while Rybelsus is a daily pill that acts on one.
Both carry the same boxed warning for thyroid tumors and share overlapping side effects like nausea and diarrhea.
Rybelsus also reduces cardiovascular risk in adults with type 2 diabetes and existing heart disease, an indication Mounjaro does not have.
Mounjaro vs. Rybelsus Drug Summary
Mounjaro
Mounjaro (tirzepatide) is a GIP/GLP-1 receptor agonist injected once a week to manage blood sugar in adults and children 10 and older with type 2 diabetes. The dose starts low and increases roughly every four weeks up to a maintenance dose of 15 mg. Many people also use it off-label for weight loss.
Rybelsus
Rybelsus (semaglutide) is a GLP-1 receptor agonist taken as a daily pill to manage blood sugar in adults with type 2 diabetes. It also lowers cardiovascular risk in patients with existing heart disease, with the dose increasing from 3 mg to 14 mg over about two months. Some people use it off-label for weight loss.
Mounjaro vs. Rybelsus Side Effects
Mounjaro
Rybelsus
Mounjaro vs. Rybelsus Dosage
Mounjaro
Rybelsus
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 3 mg once daily | Days 1-30 |
| Maximum dose | 14 mg once daily | Day 61 onward |
| Dose changes | 2 increases | Every 30 days |
Mounjaro
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
Rybelsus
| STAGE | DOSE | WHEN |
| Starting dose | 3 mg once daily | Days 1-30 |
| Maximum dose | 14 mg once daily | Day 61 onward |
| Dose changes | 2 increases | Every 30 days |
Mounjaro vs. Rybelsus Indications
Mounjaro
Mounjaro is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is not approved for type 1 diabetes or as a standalone weight-loss drug, though many prescribers use it off-label for that purpose.
Blood sugar control in adults with type 2 diabetes
Blood sugar control in pediatric patients 10 and older
Off-label: weight loss in people without diabetes
Not approved for type 1 diabetes
Rybelsus
Rybelsus is FDA-approved to improve blood sugar control in adults with type 2 diabetes and to reduce cardiovascular risk in those with existing heart disease. It is not approved for type 1 diabetes or chronic weight management, though it is sometimes used off-label for weight loss.
Blood sugar control in adults with type 2 diabetes
Reduces cardiovascular risk with existing heart disease
Off-label: weight loss in people without diabetes
Not approved for type 1 diabetes or weight management
Mounjaro vs. Rybelsus Pros and Cons
Mounjaro
Mounjaro's dual-hormone mechanism is linked to larger average reductions in blood sugar and weight than single-pathway GLP-1 drugs, but it requires a weekly injection rather than a pill. Insurance coverage varies and often hinges on a documented type 2 diabetes diagnosis.
Pros
Dual GIP/GLP-1 action often produces larger blood sugar and weight reductions
Approved for children 10 and older with type 2 diabetes
Weekly injection means fewer doses to remember than a daily pill
Flexible dose range up to 15 mg for patients needing more control
Cons
Requires a weekly self-injection rather than a pill
Not approved for cardiovascular risk reduction
Slightly higher reported vomiting rate in trials
No pediatric data below age 10
Rybelsus
Rybelsus offers the convenience of an oral tablet, which appeals to people who prefer to avoid injections, but it requires strict fasting and water rules each morning to absorb properly. It is the only GLP-1 drug also approved to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.
Pros
Oral tablet avoids the need for injections
Only oral GLP-1 approved to reduce cardiovascular risk
Longer track record, approved since 2019
Simpler three-step dose titration schedule
Cons
Must be taken on an empty stomach with a small sip of water
Cannot eat or drink for 30 minutes after taking it
Not approved for pediatric use or chronic weight management
Highest reported nausea rate between the two drugs
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.